title: Thalidomide is a highly effective treatment  of MDS: a single-hospital experience in Japan.
authors.forename: Kunio
authors.initials: K
authors.lastname: Hayashi
authors.forename: Keiko
authors.initials: K
authors.lastname: Hattori
authors.forename: Fumiharu
authors.initials: F
authors.lastname: Toi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide
references.citation: Br J Haematol. 2001 Dec;115(4):881-94
references.pmid: 11843822
references.citation: Blood. 2001 Aug 15;98(4):958-65
references.pmid: 11493439
references.citation: Oncologist. 2002;7 Suppl 1:39-49
references.pmid: 11961208
references.citation: Mayo Clin Proc. 2006 Jan;81(1):104-30
references.pmid: 16438486
references.citation: Blood. 2006 Jul 15;108(2):419-25
references.pmid: 16609072
references.citation: Leukemia. 2002 Jan;16(1):1-6
references.pmid: 11840256
references.citation: Blood. 1997 Mar 15;89(6):2079-88
references.pmid: 9058730
references.citation: Ann Hematol. 2005 Jul;84(7):479-81
references.pmid: 15800786